Literature DB >> 17052929

Neuroimaging findings in infantile GM1 gangliosidosis.

Ilknur Erol1, Füsun Alehan, M Ali Pourbagher, Oguz Canan, S Vefa Yildirim.   

Abstract

GM1 gangliosidosis is an autosomal recessive glycosphingolipid storage disease caused by defects in the enzyme beta-galactosidase. Three clinical forms (infantile-, juvenile-, and adult-onset) of the disease are recognized. Patients with infantile GM1 gangliosidosis present at birth or shortly thereafter with somatic and bony changes, followed by severe neurological deterioration ultimately leading to death within the first 2 years of life. We present the brain CT, MRI and MR spectroscopy (MRS) findings in a 17-month-old Turkish girl with infantile GM1 gangliosidosis. Neuroimaging findings in patients with infantile GM1 gangliosidosis have been reported only in a few cases. In this study, MRS of the thalamus was performed to study the metabolic changes in GM1 gangliosidosis. We showed a a decreased NAA/Cr ration and an increased Cho/Cr ratio. To our knowledge, this is the first report of magnetic resonance spectroscopy findings in type-1 GM1 gangliosidosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052929     DOI: 10.1016/j.ejpn.2006.08.005

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  10 in total

1.  Chronic GM1 Gangliosidosis with Characteristic "Wish Bone Sign" on Brain MRI. Another Type of Neurodegeneration with Brain Iron Accumulation?

Authors:  Omkar Hajirnis; Anaita Udwadia-Hegde
Journal:  Mov Disord Clin Pract       Date:  2015-06-02

2.  Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.

Authors:  Heather L Gray-Edwards; Debra S Regier; Jamie L Shirley; Ashley N Randle; Nouha Salibi; Sarah E Thomas; Yvonne L Latour; Jean Johnston; Gretchen Golas; Annie S Maguire; Amanda R Taylor; Donald C Sorjonen; Victoria J McCurdy; Peter W Christopherson; Allison M Bradbury; Ronald J Beyers; Aime K Johnson; Brandon L Brunson; Nancy R Cox; Henry J Baker; Thomas S Denney; Miguel Sena-Esteves; Cynthia J Tifft; Douglas R Martin
Journal:  Mol Ther       Date:  2017-02-22       Impact factor: 11.454

Review 3.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 4.  Bilateral symmetrical basal ganglia and thalamic lesions in children: an update (2015).

Authors:  Giulio Zuccoli; Michael Paul Yannes; Raffaele Nardone; Ariel Bailey; Amy Goldstein
Journal:  Neuroradiology       Date:  2015-07-31       Impact factor: 2.804

5.  Serial MRI features of canine GM1 gangliosidosis: a possible imaging biomarker for diagnosis and progression of the disease.

Authors:  Daisuke Hasegawa; Osamu Yamato; Yuya Nakamoto; Tsuyoshi Ozawa; Akira Yabuki; Kazuhito Itamoto; Takayuki Kuwabara; Michio Fujita; Kimimasa Takahashi; Shunta Mizoguchi; Hiromitsu Orima
Journal:  ScientificWorldJournal       Date:  2012-03-12

6.  Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.

Authors:  Igor Nestrasil; Alia Ahmed; Josephine M Utz; Kyle Rudser; Chester B Whitley; Jeanine R Jarnes-Utz
Journal:  Mol Genet Metab       Date:  2017-12-20       Impact factor: 4.797

7.  Axonopathy and Reduction of Membrane Resistance: Key Features in a New Murine Model of Human GM1-Gangliosidosis.

Authors:  Deborah Eikelberg; Annika Lehmbecker; Graham Brogden; Witchaya Tongtako; Kerstin Hahn; Andre Habierski; Julia B Hennermann; Hassan Y Naim; Felix Felmy; Wolfgang Baumgärtner; Ingo Gerhauser
Journal:  J Clin Med       Date:  2020-04-02       Impact factor: 4.241

8.  Cysts in White Matter: A Novel Neuroimaging Finding in Infantile GM1 Gangliosidosis.

Authors:  Mahesh Kamate
Journal:  Ann Indian Acad Neurol       Date:  2018 Jan-Mar       Impact factor: 1.383

9.  7T MRI Predicts Amelioration of Neurodegeneration in the Brain after AAV Gene Therapy.

Authors:  Heather L Gray-Edwards; Anne S Maguire; Nouha Salibi; Lauren E Ellis; Taylor L Voss; Elise B Diffie; Jey Koehler; Ashley N Randle; Amanda R Taylor; Brandon L Brunson; Thomas S Denney; Ronald J Beyers; Atoska S Gentry; Amanda L Gross; Ana R Batista; Miguel Sena-Esteves; Douglas R Martin
Journal:  Mol Ther Methods Clin Dev       Date:  2019-12-24       Impact factor: 6.698

10.  Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience.

Authors:  Rita Fischetto; Valentina Palladino; Maria M Mancardi; Thea Giacomini; Stefano Palladino; Alberto Gaeta; Maja Di Rocco; Lucia Zampini; Giuseppe Lassandro; Vito Favia; Maria E Tripaldi; Pietro Strisciuglio; Alfonso Romano; Mariasavina Severino; Amelia Morrone; Paola Giordano
Journal:  Mol Genet Genomic Med       Date:  2020-08-11       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.